Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Baiba Hedegaard Hansen; Jamal Abed Hanash; Alice Rasmussen; Jørgen Fischer Hansen; Morten Birket-Smith; Baiba Hedegaard Hansen; Jamal Abed Hanash; Alice Rasmussen; Jørgen Fischer Hansen; Morten Birket-Smith

doi:10.1186/1745-6215-10-20

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Baiba Hedegaard Hansen, Jamal Abed Hanash, Alice Rasmussen, Jørgen Fischer Hansen, Morten Birket-Smith, Baiba Hedegaard Hansen, Jamal Abed Hanash, Alice Rasmussen, Jørgen Fischer Hansen, Morten Birket-Smith

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

17 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009

Originalsprog	Engelsk
Tidsskrift	Trials
Vol/bind	10
Sider (fra-til)	20
ISSN	1745-6215
DOI	https://doi.org/10.1186/1745-6215-10-20 https://doi.org/10.1186/1745-6215-10-20
Status	Udgivet - 2009

Bibliografisk note

Keywords: Acute Coronary Syndrome; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Research Design; Serotonin Uptake Inhibitors; Treatment Outcome

Adgang til dokumentet

Citationsformater

Hansen, B. H., Hanash, J. A., Rasmussen, A., Hansen, J. F., Birket-Smith, M., Hansen, B. H., Hanash, J. A., Rasmussen, A., Hansen, J. F., & Birket-Smith, M. (2009). Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). Trials, 10, 20. https://doi.org/10.1186/1745-6215-10-20, https://doi.org/10.1186/1745-6215-10-20

Hansen, BH, Hanash, JA, Rasmussen, A, Hansen, JF, Birket-Smith, M, Hansen, BH, Hanash, JA, Rasmussen, A, Hansen, JF & Birket-Smith, M 2009, 'Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)', Trials, bind 10, s. 20. https://doi.org/10.1186/1745-6215-10-20, https://doi.org/10.1186/1745-6215-10-20

@article{fdb64ed088d111df928f000ea68e967b,

title = "Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)",

abstract = "BACKGROUND: The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome. METHODS: Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis of depression and Hamilton Depression Scale are the primary outcome measures. DISCUSSION: This is the first study of prevention of depression in patients after acute coronary syndrome with a selective serotonin reuptake inhibitor. TRIAL REGISTRATION: http://www.ClinicalTrials.gov. Identifier: NCT00140257.",

author = "Hansen, {Baiba Hedegaard} and Hanash, {Jamal Abed} and Alice Rasmussen and Hansen, {J{\o}rgen Fischer} and Morten Birket-Smith and Hansen, {Baiba Hedegaard} and Hanash, {Jamal Abed} and Alice Rasmussen and Hansen, {J{\o}rgen Fischer} and Morten Birket-Smith",

note = "Keywords: Acute Coronary Syndrome; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Research Design; Serotonin Uptake Inhibitors; Treatment Outcome",

year = "2009",

doi = "10.1186/1745-6215-10-20",

language = "English",

volume = "10",

pages = "20",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

AU - Hansen, Baiba Hedegaard

AU - Hanash, Jamal Abed

AU - Rasmussen, Alice

AU - Hansen, Jørgen Fischer

AU - Birket-Smith, Morten

AU - Hansen, Baiba Hedegaard

AU - Hanash, Jamal Abed

AU - Rasmussen, Alice

AU - Hansen, Jørgen Fischer

AU - Birket-Smith, Morten

N1 - Keywords: Acute Coronary Syndrome; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Research Design; Serotonin Uptake Inhibitors; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - BACKGROUND: The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome. METHODS: Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis of depression and Hamilton Depression Scale are the primary outcome measures. DISCUSSION: This is the first study of prevention of depression in patients after acute coronary syndrome with a selective serotonin reuptake inhibitor. TRIAL REGISTRATION: http://www.ClinicalTrials.gov. Identifier: NCT00140257.

AB - BACKGROUND: The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome. METHODS: Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis of depression and Hamilton Depression Scale are the primary outcome measures. DISCUSSION: This is the first study of prevention of depression in patients after acute coronary syndrome with a selective serotonin reuptake inhibitor. TRIAL REGISTRATION: http://www.ClinicalTrials.gov. Identifier: NCT00140257.

U2 - 10.1186/1745-6215-10-20

DO - 10.1186/1745-6215-10-20

M3 - Journal article

C2 - 19351383

SN - 1745-6215

VL - 10

SP - 20

JO - Trials

JF - Trials

ER -